Latest Hotspot

Accutar Reveals Phase 1 Results for AC699 in ER+/HER2- Breast Cancer at ASCO 2024

7 June 2024
3 min read

Accutar Biotechnology, Inc., a biotech firm specializing in AI-driven drug discovery, has shared findings from an ongoing Phase 1 clinical trial of AC699 as a monotherapy for patients with locally advanced or metastatic ER-positive / HER2-negative breast cancer. These results will be showcased in a poster discussion at the upcoming American Society of Clinical Oncology Annual Meeting in Chicago, IL, scheduled for June 1, 2024.

👇Discover comprehensive information about this drug, from its R&D status, core patents, clinical trials to approval status in global countries, by simply clicking on the image below. Dive deep into our drug database now.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

AC699 is an effective and selective orally bioavailable chimeric degrader targeting the estrogen receptor (ER) α. It represents a potential novel treatment option for breast cancer by employing a unique mechanism of action, which differs from fulvestrant and other novel SERDs, and shows enhanced ERα degradation as indicated by preclinical data. 

AC699 is currently under evaluation in an ongoing Phase 1 clinical trial as monotherapy for patients with ER-positive / HER2-negative locally advanced or metastatic breast cancer. The primary goals of the study are to assess the safety and tolerability of AC699. Secondary and exploratory aims involve the study of pharmacokinetics, initial efficacy, and pharmacodynamic properties. This clinical trial follows a 3+3 dose-escalation design, administering AC699 orally once daily at doses of 100, 200, 300, 400, and 600 mg.

"We are very encouraged by the remarkable safety and efficacy that AC699 has shown in Phase 1, indicating its best-in-class potential, particularly for patients with ESR1 mutations," stated Jie Fan, Ph.D., the Chief Executive Officer of Accutar Biotechnology, Inc. "We eagerly anticipate completing the dose escalation phase and commencing Phase 2 soon. We believe that the oral administration of AC699 and its distinct mechanism of action, compared to fulvestrant and other novel SERDs, could offer a new, safe, and efficient treatment option for this patient group," Jie Fan added.

👇Explore the most recent advancements in drug research, indications, organizations, clinical trials, results, and patents related to this target by clicking the image link below. Dive in to gain deeper insights!

图形用户界面, 文本, 应用程序, 表格

描述已自动生成

According to the data provided by the Synapse Database, As of June 7, 2024, there are 479 investigational drugs for the ER targets, including 259 indications, 467 R&D institutions involved, with related clinical trials reaching 4084, and as many as 132932 patents.

AC-699 is a drug of unknown type that targets the ER and is being developed for the treatment of ER-positive/HER2-negative breast cancer, as well as neoplasms, skin, and musculoskeletal diseases. It is being developed by Accutar Biotechnology, Inc. and has reached Phase 1 of development globally.

图形用户界面, 文本, 应用程序

描述已自动生成

Pharma Frontiers: Daily Digest of Global Pharmaceutical News - Jun 7
Pharma Frontiers
15 min read
Pharma Frontiers: Daily Digest of Global Pharmaceutical News - Jun 7
7 June 2024
Jun 7th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
Read →
European Commission Approves Biogen’s QALSODY® for Rare Genetic ALS
Latest Hotspot
3 min read
European Commission Approves Biogen’s QALSODY® for Rare Genetic ALS
7 June 2024
The European Commission has approved Biogen's QALSODY® (tofersen), a pioneering treatment for a rare genetic type of ALS.
Read →
Immunocore Unveils Phase 1 Brenetafusp (IMC-F106C) Results in Melanoma Patients at ASCO 2024
Latest Hotspot
3 min read
Immunocore Unveils Phase 1 Brenetafusp (IMC-F106C) Results in Melanoma Patients at ASCO 2024
7 June 2024
Immunocore reveals new Phase 1 results for brenetafusp (IMC-F106C), a bispecific ImmTAC targeting PRAME, in melanoma patients previously treated with immune checkpoint inhibitors at ASCO 2024.
Read →
Actym Therapeutics Reveals IND Approval for Phase 1 Trial of ACTM-838 in Solid Tumor Patients
Latest Hotspot
3 min read
Actym Therapeutics Reveals IND Approval for Phase 1 Trial of ACTM-838 in Solid Tumor Patients
7 June 2024
Actym Therapeutics revealed that the U.S. FDA allowing the commencement of a Phase 1 clinical trial for its primary drug candidate, ACTM-838.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.